KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Equity Ratio (2019 - 2025)

Historic Equity Ratio for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to 0.5.

  • Royalty Pharma's Equity Ratio fell 1254.15% to 0.5 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.5, marking a year-over-year decrease of 1254.15%. This contributed to the annual value of 0.57 for FY2024, which is 780.14% down from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Equity Ratio is 0.5, which was down 1254.15% from 0.52 recorded in Q2 2025.
  • Royalty Pharma's 5-year Equity Ratio high stood at 0.63 for Q2 2021, and its period low was 0.5 during Q3 2025.
  • Moreover, its 5-year median value for Equity Ratio was 0.58 (2022), whereas its average is 0.58.
  • As far as peak fluctuations go, Royalty Pharma's Equity Ratio surged by 865.7% in 2023, and later tumbled by 1254.15% in 2025.
  • Over the past 5 years, Royalty Pharma's Equity Ratio (Quarter) stood at 0.59 in 2021, then dropped by 3.17% to 0.57 in 2022, then grew by 8.66% to 0.62 in 2023, then decreased by 7.8% to 0.57 in 2024, then decreased by 12.38% to 0.5 in 2025.
  • Its last three reported values are 0.5 in Q3 2025, 0.52 for Q2 2025, and 0.56 during Q1 2025.